A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is an exploratory, randomized, double-blind, multicenter, placebo-controlled study
with repeated doses of AP1189. The study population will consist of patients with idiopathic
membranous nephropathy (iMN) who are on ACE inhibitor or angiotensin II receptor blocker
treatment.